10 tissue plasminogen activator in a stroke patient treated with dabigatran,” Cerebrovascular Diseases, vol. 30, no. 5, pp. 533– 534, 2010. [61] ClinicalTrials.gov, “IMS III,” 2006, http://clinicaltrials.gov/ ct2/show/NCT00359424. [62] H. C. Diener, S. J. Connolly, M. D. Ezekowitz et al., “Dabiga- tran compared with warfarin in patients with atrial ﬁbrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial,” The Lancet Neurology, vol. 9, no. 12, pp. 1157–1163, 2010. [63] European Stroke Organization, Guidelines for Stroke Manag- ement, 2009, http://www.eso-stroke.org/recommendations .php?cid=9&sid=1. [64] M. Watanabe, F. M. Siddiqui, and A. I. Qureshi, “Inci- dence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment,” Neurocritical Care, vol. 16, no. 1, pp. 203–209, 2012. [65] W. Zhou, S. Schwarting, S. Illanes et al., “Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran,” Stroke, vol. 42, pp. 3594–3599, 2011. Thrombosis